Results From PCA3 Research Needs Prioritization Survey

Steven I Gutman; Denise M Oliansky; Suzanne Belinson; Naomi Aronson

Appendix FResults From PCA3 Research Needs Prioritization Survey

Publication Details

Table F.1

Results from PCA3 future research needs prioritization survey.

Publication Details

Copyright

Publisher

Agency for Healthcare Research and Quality (US), Rockville (MD)

NLM Citation

Gutman SI, Oliansky DM, Belinson S, et al. PCA3 Testing in the Diagnosis and Management of Prostate Cancer: Future Research Needs: Identification of Future Research Needs From Comparative Effectiveness Review No. 98 [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Apr. (Future Research Needs Papers, No. 24.) Appendix F, Results From PCA3 Research Needs Prioritization Survey.

Table F.1Results from PCA3 future research needs prioritization survey

Rank	Research need	Total votes	Total Score
1	Lack of information on the comparative performance of PCA3 and currently used biomarkers to detect prostate cancer; lack of “matched studies” on comparators	4	11
2	Lack of studies on how PCA3 actually helps in treatment decisionmaking	4	8
3	Lack of information on the impact of PCA3 on short term outcomes such as biopsy decisionmaking	4	7
4	Uncertainty of impact of PCA3 in biopsy decisionmaking on long-term health outcomes	3	6
5	Lack of a definition of “clinically significant improvement” in diagnostic accuracy	2	5
6	Potential for comparisons of PCA3 with tPSA to be affected by inadequate clinical characterization of populations studied (e.g. verification bias)	3	4
6	Lack of clear endpoint to establish performance; when PCA3 disagrees with other inclusion criteria how do you know which is right?	2	4
7	Lack of information on the impact of PCA3 in treatment decisionmaking on long-term health outcomes	2	3
8	Lack of information on how demographics impact PCA3 test	0	0